中国标准连续出版物号：CN11-5457/R　　邮发代号：24-81　　国内定价：25.00元

中国病原生物学杂志　二〇二四年十月　第十九卷　第十期　中华预防医学会系列杂志

ISSN 1673-5234
CN 11-5457/R

中国病原生物学杂志

ZHONGGUO BINGYUAN SHENGWUXUE ZAZHI

2024年10月第19卷第10期　（总第214期）　Oct. 2024 Vol. 19, No. 10

国家疾病预防控制局　主管
中华预防医学会　主办
山东省寄生虫病防治研究所

GPB

JOURNAL OF PATHOGEN BIOLOGY

中文核心期刊（基础医学类）
中国科学引文数据库（CSCD）来源期刊
中国科技核心期刊
中国生物医学类核心期刊
RCCSE中国核心学术期刊
科技期刊世界影响力指数(WJCI)报告收录期刊
中国科技论文统计源期刊
《中国学术期刊综合评价数据库》来源期刊
《中国核心期刊（遴选）数据库》收录期刊

ISSN 1673-5234
9 771673 523110 10>

中华预防医学会系列杂志
SERIAL JOURNAL OF CHINESE PREVENTIVE MEDICINE ASSOCIATION

10
2024

北京大学图书馆 PEKING UNIVERSITY LIBRARY

《中文核心期刊要目总览》2023年版入编通知

《中国病原生物学杂志》主编先生/女士：

我们谨此郑重通知：依据文献计量学的原理和方法，经研究人员对相关文献的检索、统计和分析，以及学科专家评审，贵刊**《中国病原生物学杂志》**入编《中文核心期刊要目总览》2023年版（即第10版）之**基础医学**类的核心期刊。

《中文核心期刊要目总览》2023年版从2021年10月开始研究，研究工作由北京大学图书馆主持，共 32 个单位的 148 位专家和工作人员参加了本项研究工作，全国各地 9473 位学科专家参加了核心期刊表的评审工作。经过定量筛选和专家定性评审，从我国正在出版的中文期刊中评选出 1987 种核心期刊。

评选核心期刊的工作是运用科学方法对各种刊物在一定时期内所刊载论文的学术水平和学术影响力进行综合评价的一种科研活动。该研究成果只是一种参考工具书，主要是为图书情报界、出版界等需要对期刊进行评价的用户提供参考，例如为各图书情报部门的中文期刊采购和读者导读服务提供参考帮助等，不应作为评价标准。谨此说明。

顺颂

撰安

编号：2023-J41898

《中文核心期刊要目总览》
2023年版编委会

inflammatory cytokines is associated with sterilization [J]. PLoS Pathog, 2015, 11(1): e1004603.

[16] Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis [J]. Nat Rev Immunol, 2017, 17(11): 691-702.

[17] McCaffrey EF, Donato M, Keren L, et al. The immunoregulatory landscape of human tuberculosis granulomas [J]. Nat Immunol, 2022, 23(2): 318-329.

[18] Marakalala MJ, Raju RM, Sharma K, et al. Inflammatory signaling in human tuberculosis granulomas is spatially organized [J]. Nat Med, 2016, 22(5): 531-538.

[19] Organization WH. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-susceptible tuberculosis treatment [M]. World Health Organization, 2022.

[20] Kapoor N, Pawar S, Sirakova TD, et al. Human granuloma in vitro model, for TB dormancy and resuscitation[J]. PLoS One, 2013, 8(1): e53657.

[21] Guirado E, Mbawuike U, Keiser TL, et al. Characterization of host and microbial determinants in individuals with latent tuberculosis infection using a human granuloma model [J]. mBio, 2015, 6(1): e02537-14.

[22] Silva-Miranda M, Ekaza E, Breiman A, et al. High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against *Mycobacterium tuberculosis* [J]. Antimicrob Agents Chemotherapy, 2015, 59(1): 693-697.

[23] Arbues A, Schmidiger S, Kammuller M, et al. Extracellular matrix-induced GM-CSF and hypoxia promote immune control of *Mycobacterium tuberculosis* in human *in vitro* granulomas [J]. Front Immunol, 2021, 12: 727508.

[24] Crouser ED, White P, Caceres EG, et al. A novel in vitro human granuloma model of sarcoidosis and latent tuberculosis infection [J]. Am J Resp Cell Mol Biol, 2017, 57(4): 487-498.

[25] Puissegur MP, Botanch C, Duteyrat JL, et al. An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells [J]. Cell Microbiol, 2004, 6(5): 423-433.

[26] Nakamizo S, Sugiura Y, Ishida Y, et al. Activation of the pentose phosphate pathway in macrophages is crucial for granuloma formation in sarcoidosis [J]. J Clin Invest, 2023, 133(23): e171088.

[27] Dunlap MD, Howard N, Das S, et al. A novel role for C-C motif chemokine receptor 2 during infection with hypervirulent *Mycobacterium tuberculosis* [J]. Mucosal Immunol, 2018, 11(6): 1727-1742.

[28] Ramey ME, Kaya F, Bauman AA, et al. Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model [J]. Antimicrobial Agents Chemotherapy, 2023, 67(11): e0059723.

[29] Foss CA, Ordonez AA, Naik R, et al. PET/CT imaging of CSF1R in a mouse model of tuberculosis [J]. Eur J Nuc Med Mol Imag, 2022, 49(12): 4088-4096.

[30] Corleis B, Bastian M, Hoffmann D, et al. Animal models for COVID-19 and tuberculosis [J]. Front Immunol, 2023, 14: 1223260.

[31] Davis JM, Clay H, Lewis JL, et al. Real-time visualization of *Mycobacterium*-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos [J]. Immunity, 2002, 17(6): 693-702.

[32] van Alen I, Aguirre Garcia MA, Maaskant JJ, et al. *Mycobacterium tuberculosis* β-lactamase variant reduces sensitivity to ampicillin/avibactam in a zebrafish-Mycobacterium marinum model of tuberculosis [J]. Sci Re, 2023, 13(1): 15406.

[33] Saelens JW, Sweeney MI, Viswanathan G, et al. An ancestral mycobacterial effector promotes dissemination of infection [J]. Cell, 2022, 185(24): 4507-4525. e18.

[34] Manabe YC, Kesavan AK, Lopez-Molina J, et al. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome [J]. Tuberculosis (Edinburgh, Scotland), 2008, 88(3): 187-196.

[35] Flynn JL. Lessons from experimental *Mycobacterium tuberculosis* infections [J]. Microbes Infect, 2006, 8(4): 1179-1188.

[36] Parasa VR, Rahman MJ, Ngyuen Hoang AT, et al. Modeling *Mycobacterium tuberculosis* early granuloma formation in experimental human lung tissue [J]. Dis Model Mech, 2014, 7(2): 281-288.

[37] Simian M, Bissell MJ. Organoids: A historical perspective of thinking in three dimensions [J]. The Journal of cell biology, 2017, 216(1): 31-40.

[38] Parikka M, Hammaren MM, Harjula SK, et al. *Mycobacterium marinum* causes a latent infection that can be reactivated by gamma irradiation in adult zebrafish [J]. PLoS Pathog, 2012, 8(9): e1002944.

[39] Flynn JL, Chan JF, Lin PL. Macrophages and control of granulomatous inflammation in tuberculosis [J]. (1935-3456 (Electronic)).

[40] Pagan AJ, Ramakrishnan L. The formation and function of granulomas [J]. An Rev Immunol, 2018, 36: 639-665.

[41] Cohen SB, Gern BH, Urdahl KB. The tuberculous granuloma and preexisting immunity [J]. An Rev Immunol, 2022, 40: 589-614.

[42] Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, et al. Long-term expanding human airway organoids for disease modeling [J]. EMBO J, 2019, 38(4): e100300.

[43] Holokai L, Chakrabarti J, Broda T, et al. Increased programmed death-ligand 1 is an early epithelial cell response to *Helicobacter pylori* infection [J]. PLoS Pathog, 2019, 15(1): e1007468.

[44] Vazquez-Armendariz AI, Tata PR. Recent advances in lung organoid development and applications in disease modeling [J]. JClinical Invest, 2023, 133(22): e170500.

【收稿日期】 2024-04-30 **【修回日期】** 2024-07-20